☆ 4.7 Article

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

EBIOMEDICINE (2021)

Related references

Note: Only part of the references are listed.

Letter Immunology

Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV

Jake A. Ruddy et al.

Summary: In a study involving 12 people with HIV who received the first dose of SARS-CoV-2 mRNA vaccination, detectable anti-SARS-CoV-2 receptor-binding domain antibodies were found in all participants; those with lower CD4(+) counts showed lower antibody levels, and vaccine reactions were generally mild.

AIDS (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Article Infectious Diseases

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study

Benaya Rozen-Zvi et al.

Summary: Kidney transplant recipients showed a low antibody response rate of 36.4% after receiving the SARS-CoV-2 mRNA vaccine. Factors associated with antibody response include estimated glomerular filtration rate, medication dosage, age, and calcineurin inhibitor blood level.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Letter Medicine, General & Internal

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Gastroenterology & Hepatology

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Liane Rabinowich et al.

Summary: Liver transplant recipients showed significantly lower immunological response to the Pfizer-BioNTech SARS-CoV-2 mRNA-based vaccine, with less than half developing sufficient levels of antibodies and lower average antibody levels compared to healthy controls. Predictors for non-response included older age, renal function and immunosuppressive medications.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Oncology

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Lindsey E. Roeker et al.

LEUKEMIA (2021)

Add to Collection

Article Hematology

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Katrin Herzog Tzarfati et al.

Summary: Patients with hematologic malignancies have a reduced immune response to the COVID-19 vaccine, with lower seropositivity rates and antibody titers, increasing their risk for severe infection.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Letter Surgery

Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2

Louis Firket et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Article Hematology

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Lindsey E. Roeker et al.

BLOOD (2021)

Add to Collection

Article Hematology

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

Binod Dhakal et al.

BLOOD (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Ilies Benotmane et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Allergy

Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity

David Hagin et al.

Summary: The study evaluated the humoral and cellular immune response to the COVID-19 vaccine in patients with IEI, finding that most patients were able to develop vaccine-specific antibody response and S-protein-specific cellular response, and no significant adverse events were reported during the vaccination process.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients

Rabah Redjoul et al.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Nassim Kamar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Oncology

COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies

Jason D. Goldman et al.

Summary: This review examines the impact of SARS-CoV-2 infection on mortality in populations with distinct forms of immunocompromise and discusses the immune dysregulation in COVID-19. It suggests that certain immunosuppressants may have varying effects on different populations, providing insights for the treatment of COVID-19.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Hematology

Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients

Haris Ali et al.

Summary: This study retrospectively reviewed 113 allogeneic hematopoietic stem cell transplant (HCT) patients who received SARS-CoV2 vaccines, and found that the vaccines were well tolerated in this group. Common side effects included myalgias/arthralgias, fatigue, injection site pain, and liver function abnormalities, as well as neutropenia and other hematologic issues.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Article Hematology

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study

Ron Ram et al.

Summary: In this prospective evaluation, the BNT162b2 mRNA COVID-19 vaccine showed good tolerability and impressive immunogenicity in patients after allogeneic HCT or CART. While most adverse events were mild and transient, some significant hematologic events were observed, indicating the need for close monitoring of patients.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Article Biophysics

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy

Per Ljungman et al.

BONE MARROW TRANSPLANTATION (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Infectious Diseases

Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I

Nancy F. Crum-Cianflone et al.

INFECTIOUS DISEASES AND THERAPY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

DCLRE1C (ARTEMIS) mutations causing phenotypes ranging from atypical severe combined immunodeficiency to mere antibody deficiency

Timo Volk et al.

HUMAN MOLECULAR GENETICS (2015)

Add to Collection

Article Immunology

Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients

Nathalie Dhedin et al.

VACCINE (2014)

Add to Collection

Review Immunology

HIV-associated chronic immune activation

Mirko Paiardini et al.

IMMUNOLOGICAL REVIEWS (2013)

Add to Collection

Article Immunology

Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals

Pablo Tebas et al.

AIDS (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.